JNJ 53718678

Drug Profile

JNJ 53718678

Alternative Names: JNJ-678; JNJ53718678

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Janssen Sciences Ireland UC
  • Class Antivirals
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in Netherlands (PO) (NCT03002779)
  • 21 Dec 2016 Janssen Research & Development plans a phase I trial in Healthy volunteers in Netherlands (PO, Liquid) (NCT03002779)
  • 01 Nov 2016 Janssen Research & Development initiate a phase I trial in Healthy volunteers in Belgium (PO) (NCT02945007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top